JP2005524696A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005524696A5 JP2005524696A5 JP2003587800A JP2003587800A JP2005524696A5 JP 2005524696 A5 JP2005524696 A5 JP 2005524696A5 JP 2003587800 A JP2003587800 A JP 2003587800A JP 2003587800 A JP2003587800 A JP 2003587800A JP 2005524696 A5 JP2005524696 A5 JP 2005524696A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- disease
- compound
- acceptable salt
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 150000002148 esters Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000019695 Migraine disease Diseases 0.000 claims 3
- 208000002193 Pain Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- 206010027599 migraine Diseases 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- ZTOSZJPNPROTBL-FQEVSTJZSA-N 6-[(1r)-2-[4-(3-fluorophenyl)-4-hydroxypiperidin-1-yl]-1-hydroxyethyl]-3,4-dihydro-1h-quinolin-2-one Chemical compound C([C@H](O)C=1C=C2CCC(=O)NC2=CC=1)N(CC1)CCC1(O)C1=CC=CC(F)=C1 ZTOSZJPNPROTBL-FQEVSTJZSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 102000034527 Retinoid X Receptors Human genes 0.000 claims 1
- 108010038912 Retinoid X Receptors Proteins 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
Claims (7)
- （Ｒ）−６−［２−［４−（３−フルオロフェニル）−４−ヒドロキシ−１−ピペリジニル］−１−ヒドロキシエチル］−３，４−ジヒドロ−２（１Ｈ）−キノリノンもしくはこのような化合物の医薬として許容されるエステル、またはその医薬として許容される塩である化合物。
- 医薬として使用するための請求項１に記載の化合物。
- 請求項１に記載の化合物もしくはこのような化合物の医薬として許容されるエステル、またはその医薬として許容される塩を、医薬上で許容される賦形剤、稀釈剤または担体とともに含有する医薬組成物。
- 哺乳動物対象におけるＮＭＤＡ ＮＲ２Ｂレセプターの過剰活性により発症する疾病状態を処置するための医薬組成物であって、治療有効量の請求項１に記載の化合物もしくはこのような化合物の医薬として許容されるエステル、またはその医薬として許容される塩を含有する、上記医薬組成物。
- 疾病状態が、発作または脳損傷、慢性神経変性性疾病、例えばパーキンソン病、アルツハイマー病、ハンチントン病または筋萎縮性側索硬化症（ＡＬＳ）、てんかん症、痙攣性障害、疼痛、不安症、ヒト免疫不全ウイルス（ＨＩＶ）関連神経損傷、片頭痛、うつ病、統合失調症、腫瘍、麻酔後認識減退（ＰＡＣＤ）、緑内障、耳鳴、遅発性ジスキネジー、アレルギー性脳脊髄炎、オピオイド耐性、薬物乱用またはアルコール乱用であり、治療有効量の請求項１に記載の化合物もしくはこのような化合物の医薬として許容されるエステル、またはその医薬として許容される塩を含有する、請求項４に記載の医薬組成物。
- 疼痛、発作、外傷性脳損傷、パーキンソン病、アルツハイマー病、うつ病、不安症または片頭痛を処置するための、請求項５に記載の医薬組成物。
- 疼痛、発作、外傷性脳損傷、パーキンソン病、アルツハイマー病、うつ病、不安症または片頭痛を処置するための医薬の製造における、請求項１に記載の化合物もしくはこのような化合物の医薬として許容されるエステル、またはその医薬として許容される塩の使用。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37593902P | 2002-04-26 | 2002-04-26 | |
| PCT/IB2003/001556 WO2003091241A1 (en) | 2002-04-26 | 2003-04-15 | 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005524696A JP2005524696A (ja) | 2005-08-18 |
| JP2005524696A5 true JP2005524696A5 (ja) | 2006-06-08 |
Family
ID=29270728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003587800A Withdrawn JP2005524696A (ja) | 2002-04-26 | 2003-04-15 | Ｎｒ２ｂレセプターアンタゴニストとしての３，４−ジヒドロキノリン−２（１ｈ）−オン化合物。 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6713490B2 (ja) |
| EP (1) | EP1499606B8 (ja) |
| JP (1) | JP2005524696A (ja) |
| AR (1) | AR039663A1 (ja) |
| AT (1) | ATE325117T1 (ja) |
| AU (1) | AU2003219398A1 (ja) |
| BR (1) | BR0309778A (ja) |
| CA (1) | CA2483636A1 (ja) |
| DE (1) | DE60305026T2 (ja) |
| ES (1) | ES2258716T3 (ja) |
| MX (1) | MXPA04010549A (ja) |
| PA (1) | PA8572601A1 (ja) |
| TW (1) | TW200406402A (ja) |
| UY (1) | UY27776A1 (ja) |
| WO (1) | WO2003091241A1 (ja) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100491282B1 (ko) | 1996-07-24 | 2005-05-24 | 워너-램버트 캄파니 엘엘씨 | 통증 치료용 이소부틸가바 및 그의 유도체 |
| EP1673367A1 (en) * | 2003-10-08 | 2006-06-28 | Pfizer, Inc. | Fused lactam compounds |
| ES2246687B2 (es) * | 2004-02-11 | 2006-11-16 | Miguel Muñoz Saez | Utilizacion de antagonistas no peptidicos de receptores nk1 para la produccion de apoptosis en celulas tumorales. |
| EP1736474A4 (en) * | 2004-04-07 | 2010-04-21 | Kyowa Hakko Kirin Co Ltd | piperidine |
| HU226977B1 (en) * | 2004-07-29 | 2010-04-28 | Richter Gedeon Nyrt | Kynurenic acid amide derivatives, pharmaceutical compositions containing them and process for producing them |
| US9744137B2 (en) * | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| US8008253B2 (en) * | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
| JP2010043063A (ja) | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
| CA2738468A1 (en) | 2008-09-27 | 2010-04-01 | Taraxos Inc. | Topical formulations for treatment of neuropathy |
| US20120077883A1 (en) * | 2009-03-31 | 2012-03-29 | De Barros Coelho Claudia Couto | Treatment of tinnitus and associated auditory dysfunctions |
| WO2011145062A1 (en) | 2010-05-21 | 2011-11-24 | Link Research & Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
| EP2621475A1 (en) | 2010-10-02 | 2013-08-07 | Link Research&Grants Corporation | Treatment of tinnitus and related auditory dysfunctions |
| ES2627541T3 (es) | 2012-04-20 | 2017-07-28 | Ucb Pharma, S.A. | Métodos para tratar la enfermedad de Parkinson |
| CA2891122C (en) | 2012-11-14 | 2021-07-20 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4902695A (en) | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
| EP0554247B1 (en) | 1990-05-10 | 2000-04-26 | Pfizer Inc. | Neuroprotective indolone and related derivatives |
| WO1994010166A1 (en) | 1992-10-30 | 1994-05-11 | Pfizer Inc. | Neuroprotective 3,4-dihydro-2(1h)-quinolone compounds |
| US6407235B1 (en) | 2000-08-21 | 2002-06-18 | Hoffmann-La Roche Inc. | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol |
-
2003
- 2003-04-14 US US10/413,029 patent/US6713490B2/en not_active Expired - Fee Related
- 2003-04-15 EP EP03715209A patent/EP1499606B8/en not_active Expired - Lifetime
- 2003-04-15 MX MXPA04010549A patent/MXPA04010549A/es not_active Application Discontinuation
- 2003-04-15 BR BR0309778-1A patent/BR0309778A/pt not_active IP Right Cessation
- 2003-04-15 CA CA002483636A patent/CA2483636A1/en not_active Abandoned
- 2003-04-15 WO PCT/IB2003/001556 patent/WO2003091241A1/en active IP Right Grant
- 2003-04-15 AU AU2003219398A patent/AU2003219398A1/en not_active Abandoned
- 2003-04-15 AT AT03715209T patent/ATE325117T1/de not_active IP Right Cessation
- 2003-04-15 ES ES03715209T patent/ES2258716T3/es not_active Expired - Lifetime
- 2003-04-15 JP JP2003587800A patent/JP2005524696A/ja not_active Withdrawn
- 2003-04-15 DE DE60305026T patent/DE60305026T2/de not_active Expired - Fee Related
- 2003-04-24 UY UY27776A patent/UY27776A1/es not_active Application Discontinuation
- 2003-04-24 AR ARP030101424A patent/AR039663A1/es unknown
- 2003-04-25 PA PA20038572601A patent/PA8572601A1/es unknown
- 2003-04-25 TW TW092109786A patent/TW200406402A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005524696A5 (ja) | ||
| RU2006128446A (ru) | Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора | |
| KR102309973B1 (ko) | 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물 | |
| JP2009510044A5 (ja) | ||
| SG166125A1 (en) | New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimeræs disease | |
| JP2013526609A5 (ja) | ||
| EP2279727A3 (en) | Nanoparticulate aripiprazole formulations | |
| JP2003535094A5 (ja) | ||
| JP2014511891A5 (ja) | ||
| MA27185A1 (fr) | Amides substitues actifs au niveau du recepteur de cannabinoides-1 | |
| JP2011510014A5 (ja) | ||
| HRP20130041T1 (hr) | Terapijska sredstva | |
| JP2019524822A5 (ja) | ||
| RU2016131875A (ru) | Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы | |
| JP2010527993A5 (ja) | ||
| JP6215971B2 (ja) | てんかん又はてんかん−関連症侯群の予防又は治療用フェニルアルキルカルバメート化合物｛ｐｈｅｎｙｌａｌｋｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｅｐｉｌｅｐｓｙｏｒｅｐｉｌｅｐｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅ｝ | |
| RU2013130878A (ru) | Гидроксилированные производные аминотриазола в качестве агонистов рецептора alx | |
| JP2004536111A5 (ja) | ||
| RU2015148927A (ru) | Производные изохинолина, стимулирующие нейрогенез | |
| JP2016513691A5 (ja) | ||
| JP7381500B2 (ja) | 外傷性脳損傷を検出するための組成物および方法 | |
| US10647679B2 (en) | N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto | |
| RU2015104097A (ru) | Соединения мочевины и их применение в качестве ингибиторов ферментов | |
| JP2006522023A5 (ja) | ||
| JP2005508381A5 (ja) |